{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T22:56:13Z","timestamp":1789944973392,"version":"4.0.1"},"reference-count":30,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T00:00:00Z","timestamp":1187827200000},"content-version":"vor","delay-in-days":4678,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Psychiatr Scand"],"published-print":{"date-parts":[[1994,11]]},"abstract":"<jats:p>A study was conducted to survey the prescribing practices of neuroleptic doses in 100 consecutively hospitalized DSM\u2010III\u2010R schizophrenic patients. The relationship between doses and clinical and symptomatological variables was subsequently analyzed. Patients were evaluated through the Positive and Negative Syndrome Scale (PANSS). The peak mean dose in chlorpromazine equivalents was 1290 (range 250\u20137200). Haloperidol was the most commonly employed neuroleptic (67 patients). Neuroleptic doses were correlated with excitement, suspiciousness, hostility, uncooperativeness and poor impulse control. The neuroleptic doses administered in our hospital were similar to those found in other survey reports but higher than those recommended by the controlled dose\u2010response studies. The correlation found between neuroleptic doses and symptoms of disruptive behavior suggests that we employed high\u2010dose practices to treat the disruptive symptoms of schizophrenia. We concluded that it is useful to distinguish between the neuroleptic doses required to control the psychotic episode and those to treat the disruptive behavior.<\/jats:p>","DOI":"10.1111\/j.1600-0447.1994.tb01606.x","type":"journal-article","created":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T13:20:16Z","timestamp":1187875216000},"page":"354-357","source":"Crossref","is-referenced-by-count":26,"title":["Neuroleptic dose and schizophrenic symptoms"],"prefix":"10.1111","volume":"90","author":[{"given":"V.","family":"Peralta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"Cuesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Caro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Martinez\u2010Larrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,8,23]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.144.6.778"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.146.6.726"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1991.01810320063009"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1991.01810260074011"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1992.01820050018002"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.149.4.500"},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/archpsyc.1988.01800250095013","article-title":"Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses","volume":"45","author":"Baldesarini RJ","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199302000-00005"},{"key":"e_1_2_1_10_2","article-title":"Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia","author":"Peralta V.","journal-title":"Psychiatry Res"},{"key":"e_1_2_1_11_2","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association.","year":"1987"},{"issue":"298","key":"e_1_2_1_12_2","article-title":"A manual for the assessment of schizophrenia","volume":"65","author":"Landmark I.","year":"1982","journal-title":"Acta Psychiatr Scand"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1976.01770070088010"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1037\/h0076983"},{"key":"e_1_2_1_16_2","volume-title":"ECDEU assessment manual for psychopharmacology","author":"Guy W.","year":"1976"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1974.01760130021003"},{"key":"e_1_2_1_18_2","volume-title":"The Statistical Package for the Social Sciences (SPSS\/PC+): manual of reference","author":"Norusis MJ","year":"1986"},{"key":"e_1_2_1_19_2","volume-title":"Chemotherapy in psychiatry: principles and practice","author":"Baldesarini RJ","year":"1985"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.141.6.748"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.145.6.769a"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1978.tb06929.x"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.144.1.25"},{"key":"e_1_2_1_24_2","first-page":"739","article-title":"Indications for high dose chlorpromazine therapy in chronic schizophrenia","volume":"31","author":"Prien RF","year":"1970","journal-title":"Dis Nerv Syst"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.136.3.273"},{"key":"e_1_2_1_26_2","first-page":"569","article-title":"Carbamazepine in violent non\u2010epileptic schizophrenics","volume":"20","author":"Luchins DL","year":"1984","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800310072009"},{"key":"e_1_2_1_28_2","first-page":"117","article-title":"Parenteral lorazepam versus haloperidol for the control of psychotic disruptive behavior","volume":"52","author":"Salzman C.","year":"1991","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198402000-00005"},{"key":"e_1_2_1_30_2","first-page":"164","article-title":"A role for high\u2010dose antipsychotics","volume":"51","author":"Brotman AW","year":"1990","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/19.2.287"}],"container-title":["Acta Psychiatrica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0447.1994.tb01606.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0447.1994.tb01606.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T17:05:13Z","timestamp":1698167113000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0447.1994.tb01606.x"}},"subtitle":["A survey of prescribing practices"],"short-title":[],"issued":{"date-parts":[[1994,11]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1994,11]]}},"alternative-id":["10.1111\/j.1600-0447.1994.tb01606.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0447.1994.tb01606.x","archive":["Portico"],"relation":{},"ISSN":["0001-690X","1600-0447"],"issn-type":[{"value":"0001-690X","type":"print"},{"value":"1600-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,11]]}}}